About

Welcome to Psychedelic Nursing UK

We are a group of UK Nurses with a special interest in the upcoming awakening in the healthcare sector to natural and ancient medicine known as psychedelic drugs.

Approximately 100 million people in the world suffer with treatment-resistant depression, which means they have not responded to at least two antidepressant treatments for their depressive disorder.

More and more evidence is emerging following the release of groundbreaking results from the Royal College of Psychiatrists on the use of psilocybin to treat depression in 2018 that Psyhedelic drugs can have a positive affect on Mental Health Issues.

The Parliamentary Office of Science and Technology (POST) will publish further work on the use of psychedelic drugs for a wider range of mental health conditions, its role in elucidating other aspects of brain function, and stakeholder perspectives on their use, later in 2023. 

The future of healthcare is actually looking back in time to ancient medicine as treatment and we at Psychedelic Nursing are here to give you the latest news and updates.

What are psychedelic drugs? 

Psychedelic drugs are substances which can have a range of psychological effects on their users, such as changing sensory perceptions, thought processes, and energy levels or mood. Some occur naturally (in some plants and fungi) while others are synthesised in laboratories. The common feature of all these drugs is that they act on receptors in the central nervous system (the brain and spinal cord). Ketamine acts at glutamate receptors, while the drugs listed below target serotonin receptors: 

  • dimethyltryptamine (DMT) 
  • lysergic acid diethylamide (LSD) 
  • 3,4-methylenedioxymethamfetamine (MDMA, also known as ecstasy) 
  • mescaline 
  • psilocybin 

Current legal status on psychedelic drugs in the UK 

The production, supply and possession and distribution of drugs is controlled under the Misuse of Drugs Act (1971). The Misuse of Drugs Regulations 2001 allows for lawful possession of drugs for medicinal or therapeutic uses. Schedule 1 includes all the drugs listed above (except ketamine); they are classified on the basis that they have no therapeutic value. These drugs may be researched but require a special licence from the Home Office. Schedule 2 drugs (ketamine) can be prescribed, lawfully possessed and supplied by doctors and pharmacists and researched without a controlled drugs licence. 

In order to conduct research into most psychedelics, academics must apply to the Home Office for a special licence allowing them to obtain and administer them for research purposes. There is debate as to whether psychedelic substances – such as psilocybin – should have their Schedule 1 status (the most stringent category) under the Act reduced. It is argued that this would remove barriers to researchers being able to use them in carefully controlled studies.  

Reference https://post.parliament.uk/psychedelic-drugs-to-treat-depression

Our Goals

To bring education to the about psychadelic treatments to Nurses, counsellors, therapists and other healthcare professionals.

Subscribe to My Newsletter

Consider subscribing if you don’t want to miss it when new posts go up!!

Scroll to Top